Physician

Richard Gordon, D.O.

According to 2025 Medicare claims, Richard Gordon, D.O. (NPI: 1407859259) practices hematology/oncology in the Camden, NJ market, with the plurality of this provider's patient population coming from Camden, NJ. This provider's primary affiliated billing organization is COMPREHENSIVE CANCER & HEMATOLOGY SPECIALISTS, P.C. (NPI: 1932106580; TIN: 521676914) and primary practice location at 08043-2468.

Gordon's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 537 traditional Medicare patients, billed 183,695 HCPCS/CPT codes, and received $1,334,687 in Medicare payments. The top billing code was 99215 (Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more). Part D data shows 2,539 prescription claims across 266 beneficiaries totaling $11,260,139 in drug costs, led by Calquence (Acalabrutinib Maleate). 2023 DME data shows 35 claims. Open Payments data shows 235 records totaling $5,715. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has fallen sharply in recent years, from $2,106,400 to $1,334,687. In contrast, Part D prescription costs have risen steadily, from $1,846,241 to $11,260,139. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	815	194,340	$2,106,400
2016	764	190,826	$2,067,001
2017	825	292,430	$2,552,653
2018	839	215,358	$2,138,615
2019	795	195,342	$2,077,291
2020	692	220,117	$1,981,888
2021	634	221,562	$1,595,998
2022	580	203,856	$975,380
2023	554	192,457	$1,145,551
2024	537	183,695	$1,334,687

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	291	1,456	$1,846,241
2016	276	1,576	$2,693,923
2017	310	1,878	$4,531,070
2018	344	1,925	$5,483,738
2019	319	1,908	$5,546,822
2020	297	2,200	$7,750,378
2021	315	2,812	$9,309,110
2022	308	2,945	$9,557,558
2023	286	2,453	$10,441,741
2024	266	2,539	$11,260,139

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	24	182	$13,823
2016	N/R	91	$4,599
2017	N/R	100	$13,734
2018	N/R	83	$14,558
2019	N/R	70	$8,142
2020	N/R	37	$4,906
2021	N/R	N/R	N/R
2022	N/R	N/R	N/R
2023	N/R	35	$4,656
2024	N/R	N/R	N/R

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99215	Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more	139	218	$151
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	290	619	$104
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	254	528	$66
36415	Insertion of needle into vein for collection of blood sample	334	796	$9
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	365	1,113	$8

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Calquence	Acalabrutinib Maleate	78	2,340	$1,129,647
Imbruvica	Ibrutinib	67	1,876	$1,008,029
Revlimid	Lenalidomide	60	1,680	$947,578
Pomalyst	Pomalidomide	41	1,162	$677,900
Darzalex Faspro	Daratumumab-Hyaluronidase-Fihj	49	1,057	$637,108

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	235	$5,715	Janssen Biotech, Inc.
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Richard Gordon, D.O.?

Tedicare shows public-source Medicare data for Richard Gordon, D.O. (NPI 1407859259), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Richard Gordon, D.O. have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Richard Gordon, D.O.?

Richard Gordon, D.O. is linked to COMPREHENSIVE CANCER & HEMATOLOGY SPECIALISTS, P.C. (billing NPI 1932106580) in the available physician profile data.

Does Richard Gordon, D.O. have Open Payments data?

Richard Gordon, D.O. has 235 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.